Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hyprolose; calcium hydrogen phosphate dihydrate; crospovidone - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis

Австралия - английски - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - minocycline hydrochloride dihydrate, quantity: 54 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; sodium starch glycollate; sodium lauryl sulfate; titanium dioxide; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 400 - infections due to the following organisms, provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli; enterobacter aerogenes; haemophilus influenzae; klebsiella and proteus. in addition, infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis, however, because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the organisms have definitely been shown to be sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline resistant acne.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; hyprolose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; calcium hydrogen phosphate dihydrate; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; microcrystalline cellulose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - minocycline hydrochloride dihydrate, quantity: 53.985 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; povidone; sorbitol; microcrystalline cellulose; stearic acid; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; light liquid paraffin; sodium lauryl sulfate - indications as at 12 november 2003 : minocycline may be used for the treatment of infections caused by any of the following organisms provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli, enterobacter aerogenes, haemophilus influenzae, klebsiella and proteus. it may also be used in the treatment of infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis but because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the orgaisms have been shown to be definitely sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline-resistant acne.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; hyprolose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; calcium hydrogen phosphate dihydrate; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; microcrystalline cellulose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis

Австралия - английски - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; povidone; magnesium stearate - indications as at 23 november 2004 : oral therapy - hypertension, angina pectoris prophylaxis, suspected or definite myocardial infarction, migraine prophylaxis.

Израел - английски - Ministry of Health

lapidot medical import and marketing ltd - lidocaine hydrochloride monohydrate - solution for injection - lidocaine hydrochloride monohydrate 20 mg/ml - lidocaine - local and regional anaesthesia.severe symptomatic ventricular tachycardia or tachy-arrhythmia, if assessed to be life-threatening.

Израел - английски - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 88 mcg/ml - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiplbe sclerosis has not been established.rebif is indicated for the treatment of patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.